Gossamer Bio第一季度营收达到1696万美元，超出471万美元的预期260%，但每股亏损0.20美元，未达到亏损0.17美元的预期，差距为17.65%。 盘后股价暴跌41.44%，随后在盘前反弹12.09%至0.20美元，接近52周低点0.16美元，市场波动剧烈。 该公司实施了50%的裁员并进行了债务重组，手头现金9900万美元，旨在将现金流维持到2027年第一季度。 管理层尽管面临盈利 ...

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) and ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best stocks under $3 to invest in. On February 4, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Gossamer Bio and set a $10 price ...

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a ...

Gossamer Bio Extends Gains Pre-Bell Following New Drug Application Filing Plans for Pulmonary Arterial Hypertension Treatment MT Jul. 27 Gossamer Bio, Inc. Announces Proceeding Toward Planned NDA Subm ...

Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary ...

The MarketWatch News Department was not involved in the creation of this content. - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week ...

- Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 - - At week 24, ...